Equity Research Pharmaceutical Preparations

Should You Buy United Therapeutics Corporation Stock in 2026?

By CirclFi Research Team · · 13/13 models active

According to the CirclFi Deep Alpha Valuation Engine, United Therapeutics Corporation (UTHR) ranks in the top tier of our coverage universe with a Quality of Company score of 10.0/10. Trading at a market price of $529.34, this high-quality profile requires careful comparison against our 13 intrinsic value models.

The short answer: 3 of 13 CirclFi valuation models project upside for United Therapeutics Corporation (UTHR) at $529.34 — the model consensus leans bearish, with a Quality Score of 10.0/10 and Value-Trap risk of —/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 10 of 13 models suggest overvaluation — majority bearish
  • Quality Score: 10.0/10 — Excellent — top-tier fundamentals
  • Value Trap Risk: —/100 — Not scored
  • Fair Value Range: $94.74 – $2560.15 (2602% spread)

Bullish Models

3 / 13

Bearish Models

10 / 13

Quality Score

10.0 /10

Excellent — top-tier fundamentals

Value Trap Risk

— /100
Not scored

Not scored

Model Consensus

13 /13
Active Models

Avg. confidence: 44%

Investment Thesis

The Bull Case

Target: $2560.15 (+383.6% upside)

  • According to the CirclFi Quality of Company (QOC) framework, United Therapeutics Corporation's quality score of 10.0/10 demonstrates the operational excellence that historically correlates with long-term shareholder value creation.
  • According to the CirclFi Deep Alpha Valuation Engine, the Markov DDM model targets a fair value of $2,560.15 (+383.6%), anchoring the bull case with a methodology that provides a differentiated analytical lens.
  • Industry tailwind: regulatory pathway clarity could provide meaningful support for United Therapeutics Corporation's revenue and margin trajectory in the Pharmaceutical Preparations space.

The Bear Case

Target: $94.74 (-82.1%)

  • According to the CirclFi Deep Alpha Valuation Engine, the Dynamic NAV model sees the stock as overvalued with a fair value of $94.74 (-82.1%), suggesting that the market price embeds overly optimistic growth assumptions.
  • According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +465.8% spread between the most bullish and bearish models, signaling elevated analytical uncertainty.
  • Industry headwind: clinical trial failure represents a meaningful risk for United Therapeutics Corporation and its Pharmaceutical Preparations peers.

Peer Benchmarking

AMPH Amphastar Pharmaceut
10.0
AZN AstraZeneca PLC
10.0
CPRX Catalyst Pharmaceuti
10.0
HRMY Harmony Biosciences
10.0
NVO Novo Nordisk A/S
10.0

See full Pharmaceutical Preparations rankings →

Valuation Divergence

Spread

2602%

Fair Value Range

$94.74 – $2560.15

A 2602% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

Markov DDM

$2,560.15 (+383.6%)

Most Bearish

Dynamic NAV

$94.74 (-82.1%)

Key Risk Factors

Model Disagreement

2602% spread signals high variance in projections.

Bearish Consensus

10/13 models suggest overvaluation.

Macro/Sector Risk

Pharmaceutical Preparations headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View UTHR Data Page →

The Bottom Line

Caution dominates our read on United Therapeutics Corporation at $529.34. 9 of 13 models see limited upside or outright downside, with the composite fair value at $548.59 (+3.6%). Quality at 10.0/10 provides some fundamental cushion. Current holders should re-evaluate their thesis; new buyers should demand a wider margin of safety.

These are quantitative model outputs, not investment recommendations. United Therapeutics Corporation's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

Frequently Asked Questions

Should I buy UTHR stock right now?

Based on CirclFi's multi-model analysis, 3 of 13 models see upside for UTHR at $529.34. The models are divided, which means the investment case depends heavily on your assumptions about United Therapeutics Corporation's future. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in United Therapeutics Corporation?

Key risks include: wide model disagreement (2602% spread), signaling high uncertainty; general market and sector-specific risks affecting Pharmaceutical Preparations companies. Always diversify and consult a financial advisor.

How does UTHR compare to its competitors?

Among Pharmaceutical Preparations peers, UTHR holds a Quality Score of 10.0/10. Comparable companies include AMPH (QOC 10.0), AZN (QOC 10.0), CPRX (QOC 10.0). The relative ranking helps investors identify whether UTHR offers better fundamental quality than alternatives in the same sector.

Is UTHR a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. UTHR's Quality Score of 10.0/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.

What price should I buy UTHR at?

CirclFi does not provide target buy prices or price alerts. However, our 13 active models produce fair value estimates ranging from $94.74 to $2560.15. At $529.34, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for UTHR.

View UTHR Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →